BMS adds to IBD pipeline with $1.9bn GentiBio deal
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes […]
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes […]
Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted […]
The FDA has kicked off its review of Bristol-Myers Squibb’s psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU […]
Bristol Myers Squibb drug deucravacitinib missed the main and secondary goals of a Phase 2 study in ulcerative colitis. Despite the clinical trial failure, the […]
Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure […]
Shots: The P-II LATTICE-UC study evaluates the safety and efficacy of deucravacitinib (PO) vs PBO in patients with mod. to sev. UC The trial did […]
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. The […]
Shots: The two P-III POETYK PSO-1 and POETYK PSO-2 trials evaluating deucravacitinib (6mg, qd) vs PBO & Otezla (30mg, bid) @16wks. and vs Otezla @24wks. […]
Shots: The P-III POETYK PSO-2 study involves assessing deucravacitinib (6mg, qd) vs PBO & Otezla (30mg, bid) in 1,020 patients with moderate to severe plaque […]
Shots: The P-III POETYK PSO-1 study involves assessing deucravacitinib (6mg, qd) vs PBO & Otezla (apremilast) in 666 patients with moderate to severe plaque psoriasis […]
Copyright © 2024 | WordPress Theme by MH Themes